Publications

Pembrolizumab (Pembro) Vs Standard-Of-Care (Soc) in Previously Treated Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc): 6-Year Follow-Up of Keynote-040

AuthID
P-00X-M22

Author(s)

Soulieres, D

Harrington, KJ

Le Tourneau, C

Silva, JD

Licitra, LF

Ahn, MJ

Soria, A

Machiels, JP

Mach, N

Mehra, R

Burtness, B

Lin, J

Lerman, N

Gumuscu, B

Cohen, EEW

Document Type

Abstract

Year published

2022

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 33, Issue: 7, Pages: S843-S843 (1)

Conference

Annual Meeting of the European-Society-For-Medical-Oncology (Esmo), Date: SEP 09-13, 2022, Location: ELECTR NETWORK, Sponsors: European Soc Med Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2022.07.782

Wos: WOS:000866211600649

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Pembrolizumab (Pembro) Vs Standard-Of-Care (Soc) in Previously Treated Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc): 6-Year Follow-Up of Keynote-040

Useful Links

Get Help

Federated Authentication (Click on the image)

Pembrolizumab (Pembro) Vs Standard-Of-Care (Soc) in Previously Treated Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc): 6-Year Follow-Up of Keynote-040

Useful Links

Get Help